natgillin/translations-raw huggingface dataset:
Tiny amounts of hydrochloric acid (E507) and/ or sodium hydroxide (E524) are sometimes added to keep acidity levels (pH levels) normal.
Včasih so dodane majhne količine klorovodikove kisline (E507) ali natrijevega hidroksida (E524) ali obeh za ohranjanje normalne kislosti (pH vrednosti).
What OPATANOL looks like and the contents of the pack OPATANOL is a clear liquid (a solution) supplied in a pack containing either one 5 ml plastic bottle or three 5 ml bottles with screw caps.
Izgled zdravila OPATANOL in vsebina pakiranja OPATANOL je bistra tekočina (raztopina), ki je na voljo v pakiranjih s 5 ml plastenko ali s tremi 5 ml plastenkami z navojno zaporko.
19 The marketing authorisation holder Alcon Laboratories (UK) Ltd Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom
Pentagon Park Boundary Way Hemel Hempstead Herts, HP2 7UD Velika Britanija
Manufacturer S. A.
Izdelovalec S. A.
S. A.
Izdelovalec Alcon Cusí, S. A.
Camil Fabra 58 08320 El Masnou Spain
Camil Fabra 58 08320 El Masnou Španija
20 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
20 Za vse informacije o tem zdravilu se lahko obrnete na lokalno predstavništvo imetnika dovoljenja za promet z zdravilom.
The two powders are made up into a ‘ suspension’ (a liquid with solid particles in it) with a putty-like consistency, which is implanted in the body.
Dva praška se pripravita v „ suspenzijo “ (tekočino, ki vsebuje trdne delce), ki ima vosku podobno sestavo in se vsadi v telo.
This can cause pain, instability, and problems due to pressure on the nerves, including tingling, numbness, weakness and difficulty controlling certain muscles.
To lahko povzroči bolečino, nestabilnost in težave zaradi pritiska na živce, ki vključujejo mravljince, otopelost, šibkost in težave pri nadzorovanju nekaterih mišic.
Spondylolisthesis can be treated using surgery to fuse (join) the vertebrae above and below the site where the slip occurred.
Spondilolisteza se lahko zdravi z operativnim posegom, pri kateri se združi (poveže) vretence nad in pod mestom, kjer je prišlo do drsenja.
Opgenra is used only in patients who have previously had surgery using an autograft (a bone graft taken from their own body, usually the hip) that has failed or when an autograft must not be carried out.
Zdravilo Opgenra se uporablja samo pri bolnikih, ki so že prestali operativni poseg z avtolognim presadkom (kostni presadek, ki se odvzame iz bolnikovega lastnega telesa, navadno kolka) z neuspešnim izidom ali pri tistih bolnikih, pri katerih se avtolognega presadka ne sme uporabiti.
It is a copy of a protein called osteogenic protein 1, also known as bone morphogenic protein 7 (BMP-7), which is produced naturally by the body and helps the formation of new bone tissue.
Učinkovina je kopija beljakovine, imenovane osteogeni protein 1, znane tudi kot kostni morfogeni protein 7 (BMP- 7), ki ga telo proizvaja naravno in pomaga pri tvorjenju novega kostnega tkiva.
Eptotermin alfa is produced by a method known as ‘ recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce eptotermin alfa.
Eptotermin alfa se proizvaja z metodo, imenovano „ rekombinantna DNK tehnologija “.
The replacement eptotermin alfa acts in the same way as naturally produced BMP-7.
Proizvajajo ga celice, ki so prejele gen (DNK), zaradi katerega lahko tvorijo eptotermin alfa.
Treatment was defined as ‘ successful’ when bone could be seen between the affected vertebrae on X-rays, and the patient had shown improvement in disability, with no need for further treatment of the spine, no serious side effects and no worsening of the symptoms caused by pressure on the nerves.
Zdravljenje so opredelili kot uspešno, če je bilo na rentgenskih slikah mogoče videti kostno tkivo med prizadetimi vretenci in so bolniki pokazali napredek v svojem stanju, brez potrebe po nadaljnjemu zdravljenju hrbtenice, brez resnih neželenih učinkov in brez poslabšanja simptomov, ki jih povzroča pritiskanje na živce.
After two years, treatment with Opgenra was successful in 39% of the patients, compared with 49% with autograft.
Po dveh letih je bilo zdravljenje z zdravilom Opgenra uspešno pri 39% bolnikih v primerjavi z 49% tistih, ki so prejeli avtologni presadek.
Despite the lower effectiveness, there was sufficient evidence from the study and from the published literature to support the use of Opgenra in patients in whom autograft has failed or who must not undergo the procedure.
Kljub nižji učinkovitosti je dala študija dovolj dokazov, objavljena literatura pa dovolj podpore za uporabo zdravila Opgenra pri bolnikih, pri katerih avtologni presadek ni bil uspešen ali posega ne smejo prestati.
In addition, Opgenra had advantages over autograft, including shorter operations, less blood loss and less pain.
Poleg tega ima zdravilo Opgenra prednosti pred avtolognim presadkom, vključno s krajšimi operativnimi posegi, manjšo izgubo krvi in z manj bolečinami.
The most common side effects with Opgenra (seen in between 1 and 10 patients in 100) are heterotopic bone formation (bone formation outside the fusion area) and pseudoarthrosis (failure of the spine to fuse).
Najpogostejši neželeni učinki zdravila Opgenra (opaženi pri 1 do 10 bolnikih izmed 100) so heterotopična okostenitev (tvorjenje kostnine izven območja fuzije) in psevdoartroza (neuspela spinalna fuzija).
In addition, some side effects are seen in between 1 and 10 patients in 100 following spine surgery itself, including infection after the operation, wound dehiscence (opening of the wound), secretion (seepage) and erythema (redness of the skin).
Poleg tega so nekatere neželene učinke opazili pri 1 do 10 bolnikih izmed 100 po samem operativnem posegu na hrbtenici, vključevali pa so okužbo po operaciji, dehiscenco rane (odpiranje rane), sekrecijo (mezenje) in eritem (rdečino kože).
For the full list of all side effects reported with Opgenra, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Opgenra, glejte navodilo za uporabo.
It must not be used in the following groups:  patients with an auto-immune disease (a disease caused by the body’ s own defence system attacking normal tissue);  patients who have an active infection at the operation site or have had repeated infections;  patients who do not have adequate skin covering or blood supply at the operation site;  patients who have received a medicine containing BMP in the past;  patients with cancer or being treated for cancer;  patients whose bones are still growing such as children and adolescents.
Zdravilo se ne sme uporabljati pri naslednjih skupinah bolnikov:  bolniki z avtoimunsko boleznijo (boleznijo bolnikovega lastnega obrambnega sistema, ki napada normalno tkivo),  bolniki z aktivno okužbo na mestu operativnega posega ali bolniki s ponavljajočimi se okužbami,  bolniki, ki na mestu operativnega posega nimajo zadostne prekritosti s kožo ali prekrvavljenosti,  bolniki, ki so v preteklosti že prejeli zdravilo s kostnim morfogenim proteinom (BMP),  bolniki z rakom ali bolniki, ki se zdravijo zaradi raka,  bolniki, katerih kosti še vedno rastejo, kot so otroci in mladostniki.
The Committee for Medicinal Products for Human Use (CHMP) decided that Opgenra’ s benefits are greater than its risks for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Opgenra pri posterolateralni lumbalni spinalni fuziji pri odraslih bolnikih s spondilolistezo, pri katerih avtologni presadek ni bil uspešen ali pa je kontraindiciran, večje od z njim povezanih tveganj.
Which measures are being taken to ensure the safe use of Opgenra?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Opgenra?
The company that makes Opgenra will provide educational packs and training DVDs for surgeons in each Member State.
Družba, ki proizvaja zdravilo Opgenra bo priskrbela izobraževalne pakete in DVD- plošče za usposabljanje, namenjene kirurgom v posameznih državah članicah.
These will include information on Opgenra’ s safety and remind them of how to prepare and use the medicine in an operation.
Vsebovali bodo informacije o varnosti zdravila Opgenra ter navodila za kirurge, kako pripraviti in uporabljati zdravilo v
2/ 3 Other information about Opgenra:
2/ 3 operativnem posegu.
The European Commission granted a marketing authorisation valid throughout the EU for Opgenra to Howmedica International S. de R.
Evropska komisija je dovoljenje za promet z zdravilom Opgenra, veljavno po vsej Evropski uniji, odobrila družbi Howmedica International S. de R.
L. on 19 February 2009.
L. dne 19. februarja 2009.
The full EPAR for Opgenra can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Opengra je na voljo tukaj.
After reconstitution, Opgenra contains 1 mg/ ml eptotermin alfa.
Jedna injekčná liekovka obsahuje 1 g prášku s 3, 5 mg eptotermina alfa *.
*Eptotermin alfa is human recombinant Osteogenic protein 1 (OP-1) produced in Chinese hamster ovary (CHO) cell line.
Po rekonštitúcii Opgenra obsahuje 1 mg/ ml eptotermina alfa.
In a clinical study of the medicinal product, antibodies to the protein eptotermin alfa were detected in 194 out of 207 (94%) patients treated with it and 18 out of 86 (21%) treated with autograft bone (control group).
V klinickej štúdii lieku boli protilátky na proteín eptotermina alfa detegované u 194 z 207 (94%) liečených pacientov a u 18 z 86 (21%) pacientov liečených kostným autoštepom (kontrolná skupina).
However, an immune response to eptotermin alfa should be considered and appropriate validated tests for the presence of antibodies in serum should be performed in cases where an immune-mediated undesirable effect is suspected, including cases where the medicinal product is ineffective.
Imunitná odpoveď na eptotermina alfa však musí byť braná do úvahy a musia sa uskutočňovať príslušné validované testy na prítomnosť protilátok v sére v prípadoch podozrenia na nežiaduci účinok sprostredkovaný imunitnou cestou, vrátane prípadov, keď liek nie je účinný.
Eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle.
Eptotermina alfa, liečivo, inicializuje tvorbu kostí indukovaním bunkovej diferenciácie mezenchýmových buniek, ktoré lokalitu implantátu posilňujú z kostnej drene, periostu a svalstva.
However, results from implantation studies in animals demonstrate that the active substance eptotermin alfa is released from the implant site over several weeks and never reaches a level higher than 3% of the total amount implanted in the peripheral blood.
Výsledky z implantačných štúdii na zvieratách však preukázali, že liečivo eptotermina alfa sa uvoľňuje z miesta implantácie niekoľko týždňov a nikdy nedosahuje hladinu vyššiu ako 3% z celkového implantovaného množstva v periférnej krvi.
Controlled studies of the effects of exposure to eptotermin alfa on pre and postnatal development were performed in rabbit models.
Kontrolované štúdie účinkov expozície eptotermina alfa na pre - a postnatálny vývoj sa uskutočnili na králičích modeloch.
Eptotermin alfa in Freund’s adjuvant was first administered subcutaneously with booster doses given after 14 and 28 days.
Eptotermina alfa vo Freundovom adjuvanse sa najprv podával subkutánne s posilňovacími (booster) dávkami podávanými po 14 a 28 dňoch.
Detectable levels of IgG and IgM antibodies to eptotermin alfa had developed and were found in the serum of all exposed adult animals.
Detegovateľné úrovne protilátok IgG a IgM na eptotermina alfa sa vyvinuli a boli zistené v sére všetkých exponovaných dospelých zvierat.
Antibodies to eptotermin alfa were also found in sera from pooled foetal and umbilical cord blood, at levels that correlated to that of the maternal blood.
Protilátky na eptotermina alfa boli zistené aj v krvnom sére z poolovanej krvi plodu a pupočníkovej šnúry na úrovniach korelujúcich s úrovňami v krvi matky.
Place the contents of the eptotermin alfa vial and carmellose vial in a sterile bowl.
Injekčnú liekovku s eptotermina alfa a injekčnú liekovku s karmelózou vložte do sterilnej misky.
Opgenra 3.5 mg powders for suspension for implantation eptotermin alfa
Opgenra 3, 5 mg prášok na implantačnú suspenziu eptotermina alfa
One vial containing 3.5 mg of eptotermin alfa.
Jedna injekčná liekovka obsahujúca 3, 5 mg eptotermina alfa.
After reconsistuation, Opgenra contains 1 mg/ml eptotermin alfa.
Po rekonštitúcii Opgenra obsahuje 1 mg/ ml eptotermina alfa.
1 vial containing 1 g of powder (3.5 mg eptotermin alfa).
1 injekčná liekovka obsahujúca 1 g prášku (3, 5 mg eptotermina alfa).
Opgenra 3.5 mg powder for suspension for implantation epotermin alfa Intraosseous use
Opgenra 3, 5 mg prášok na implantačnú suspenziu. eptotermina alfa Vnútrokostné použitie
1g powder (3.5 mg eptotermin alfa)
1 g prášku (3, 5 mg eptotermina alfa)
Opgenra 3.5 mg powder for suspension for implantation Eptotermin alfa Intraosseous use
Opgenra 3, 5 mg prášok na implantačnú suspenziu Eptotermina alfa 3, 5 mg Vnútrokostné použitie
1 g (3.5 mg eptotermin alfa)
1 g (3, 5 mg eptotermina alfa)
“{Patient Name} was implanted with a medicinal product containing eptotermin alfa on {dd/mm/yyy}.
„ {Meno pacienta} bol implantovaný liek obsahujúci eptotermina alfa dňa {dd/ mm/ rrrr}.
- if you are allergic (hypersensitive) to eptotermin alfa or to any of the ingredients of Opgenra
- ak ste alergický (precitlivený) na eptotermina alfa alebo na ktorúkoľvek z
(see section 6).
ďalších zložiek Opgenry (pozri časť 6).
- have had Opgenra, eptotermin alfa or any similar medicine before.
- ak ste už v minulosti dostali Opgenru, eptotermina alfa alebo iný podobný liek.
The maximum dose of this medicine should not exceed 2 units (7.0 mg eptotermin alfa) since its effectiveness and safety in higher doses has not been studied.
Maximálna dávka tohto lieku nesmie prekročiť 2 jednotky (7, 0 mg eptotermina alfa), pretože jeho efektívnosť a bezpečnosť pri vyšších dávkach nebola študovaná.
The active substance is eptotermin alfa (a recombinant human Osteogenic protein 1 produced in a recombinant Chinese hamster overy (CHO) cell line).
Liečivo je eptotermina alfa (rekombinantný humánny osteogénny proteín 1 produkovaný v rekombinantných bunkách vaječníkov čínskeho škrečka (CHO).
One vial of Opgenra contains 1 g of powder including 3,5 mg of eptotermin alfa and the excipient bovine collagen.
Jedna injekčná liekovka Opgenry obsahuje 1 g prášku s 3, 5 mg eptotermina alfa a hovädzí kolagén ako pomocnú látku.
Each outer carton contains one 3.5 mg eptotermin alfa vial containing 1 g of powder and one carmellose powder vial containing 230 mg powder.
Každý vonkajší obal obsahuje jednu liekovku s 3, 5 mg eptotermina alfa obsahujúcu 1 g prášku a jednu injekčnú liekovku s karmelózou obsahujúcu 230 mg prášku.
25/25
26 27
Oprymea is a medicine containing the active substance pramipexole base.
Oprymea je zdravilo, ki vsebuje zdravilno učinkovino pramipeksol.
It is available as white tablets (round:
Na voljo je v obliki belih tablet (okrogle:
0.088 mg, 0.7 mg and 1.1 mg; oval:
0, 088 mg, 0, 7 mg in 1, 1 mg; ovalne:
0.18 mg and 0.35 mg).
0, 18 mg in 0, 35 mg).
Oprymea is a ‘ generic medicine’.
Zdravilo Oprymea je „ generično zdravilo “.
This means that Oprymea is similar to a ‘ reference medicine’ already authorised in the European Union (EU) called Sifrol (also known as Mirapexin).
To pomeni, da je podobno „ referenčnemu zdravilu “, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Sifrol (poznanim tudi kot zdravilo Mirapexin).
Oprymea is used to treat the symptoms of Parkinson’ s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Zdravilo Oprymea se uporablja za zdravljenje simptomov Parkinsonove bolezni, napredujoče okvare možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrdelost mišic.
Oprymea can be used either on its own or in combination with levodopa (another medicine for Parkinson’ s disease), at any stage of disease including the later stages when levodopa starts becoming less effective.
Zdravilo Oprymea se lahko uporablja bodisi samostojno bodisi v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v katerem koli stadiju bolezni, vključno s poznim stadijem, ko začne učinek levodope popuščati.
Oprymea tablets should be swallowed with water, with or without food.
Tablete Oprymea je treba pogoltniti z vodo, skupaj z obrokom ali brez njega.
The starting dose is 0.088 mg three times per day.
Začetni odmerek je 0, 088 mg trikrat na dan.
The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated.
Odmerek je treba povečevati vsakih pet do sedem dni, dokler niso simptomi pod nadzorom, zdravilo pa ne povzroča nevzdržnih stranskih učinkov.
The maximum daily dose is 1.1 mg three times per day.
Največji dovoljeni dnevni odmerek je 1, 1 mg trikrat na dan.
The active substance in Oprymea, pramipexole, is a dopamine agonist, which imitates the action of dopamine.
Zdravilna učinkovina zdravila Oprymea, pramipeksol, je dopaminski agonist, ki ovira delovanje dopamina.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’ s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira možgane enako kot dopamin, tako da lahko bolniki spet nadzirajo svoje gibe in kažejo manj znakov in simptomov Parkinsonove bolezni, kot so tresenje, otrdelost mišic in upočasnjeno izvajanje gibov.
Because Oprymea is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine (they produce the same levels of the active substance in the body).
Ker je zdravilo Oprymea generično zdravilo, so bile študije omejene na teste, s katerimi se dokaže biološka enakovrednost6 referenčnemu zdravilu (zdravila dosegajo enake ravni zdravilne učinkovine v telesu).
What is the risk associated with Oprymea?
Kakšna tveganja so povezana z zdravilom Oprymea?
Because Oprymea is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je zdravilo Oprymea generično zdravilo in je biološko enakovredno referenčnemu zdravilu, iz tega izhaja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Oprymea has been shown to have comparable quality and to be bioequivalent to Sifrol.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Oprymea primerljivo raven kakovosti zdravilu Sifrol ter mu je biološko enakovredno.
Therefore, the CHMP’ s view was that, as for Sifrol, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da koristi zdravila Oprymea tako kot pri zdravilu Sifrol odtehtajo z njim povezana tveganja.
The Committee recommended that Oprymea be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Oprymea odobri dovoljenje za promet.
Other information about Oprymea:
Druge informacije o zdravilu Oprymea:
The European Commission granted a marketing authorisation valid throughout the EU for Oprymea to Krka, d. d., Novo mesto on 12 September 2008.
Evropska komisija je dovoljenje za promet z zdravilom Oprymea, veljavno po vsej Evropski uniji, odobrila družbi Krka, d. d., Novo mesto, dne 12. septembra 2008.
The full EPAR for Oprymea can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Oprymea je na voljo tukaj.
Oprymea 0.088 mg tablets
Oprymea 0, 088 mg tablete
Each tablet contains 0.088 mg pramipexole base (as 0.125 mg pramipexole dihydrochloride monohydrate).
1 tableta vsebuje 0, 088 mg pramipeksola v obliki 0, 125 mg pramipeksolijevega dihidroklorid monohidrata.
Pramipexole doses as published in the literature refer to the salt form.
Odmerki pramipeksola, kot jih navajajo v literaturi, se nanaš na sol.
Therefore, doses will be expressed in terms of both pramipexole base and pramipexole salt (in brackets).
obe obliki, pramipeksol in pramipeksolijevo sol (v oklepaju).
For a full list of excipients, see section 6.1.
Za celoten seznam pomož snovi glejte poglavje 6. 1. nih
0.088 mg: white, round, with bevelled edges and imprint "P6" on one side of the tablet.
0, 088 mg: bele, okrogle, s posnetimi robovi in oznako P6 na eni strani tablete.
CLINICAL PARTICULARS
KLINIČ PODATKI NI
Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “ on off” fluctuations).
Zdravilo Oprymea je indicirano za zdravljenje znakov in simptomov idiopatske Parkinsonove bolezni, samo ali v kombinaciji z levodopo, v napredovalem in poznem stadiju, ko zač uč levodope ne inek popušati, postane nestalen in se pojavljajo nihanja terapevtskega uč (pojemanje uč odmerka
4.2 Posology and method of administration
4. 2 Odmerjanje in nač uporabe in
Parkinson’ s disease The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
Vzamejo se lahko s hrano ali brez nje.
Initial treatment Dosages should be increased gradually from a starting-dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days.
Č bolniki ne trpijo zaradi nevzdrž než
Providing patients do not experience intolerable side-effects, the dosage should be titrated to achieve a maximal therapeutic effect.
prilagajamo, dokler ne dosež maksimalnega terapevtskega uč
Ascending – Dose Schedule of OPRYMEA Week
evanja odmerka Oprymee Teden
If a further dose increase is necessary the daily dose should be increased by 0.54 mg base (0.75 mg salt) at weekly intervals up to a maximum dose of 3.3 mg of base (4.5 mg of salt) per day.
Pri tem je treba upoš
Maintenance treatment The individual dose should be in the range of 0.264 mg of base (0.375 mg of salt) to a maximum of 3.3 mg of base (4.5 mg of salt) per day.
Vzdrž evalno zdravljenje Individualni dnevni odmerek je lahko od 0, 264 mg (0, 375 mg soli) do največ mg pramipeksola 3, 3 (4, 5 mg soli).
During dose escalation in three pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt).
Pri poveč evanju odmerka so v treh ključ š nih tudijah opazili učinkovitost pri dnevnem odmerku 1, 1 mg pramipeksola (1, 5 mg soli) in večNa osnovi klinič
Further dose adjustments should be done based on the clinical response and the occurrence of adverse reactions.
V klinič preizkuš
In clinical trials approximately 5% of patients were treated at doses below 1.1 mg (1.5 mg of salt).
anjih so približ 5% bolnikov no
In advanced Parkinson’ s disease, doses higher than 1.1 mg (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
Dnevni odmerki, več od 1, 1 mg (1, 5 mg soli), so lahko koristni pri bolnikih z napredovalo ji Parkinsonovo boleznijo, pri katerih je predvideno zdravljenje z manjš odmerki levodope.
It is recommended that the dosage of levodopa is reduced during both the dose escalation and the maintenance treatment with Oprymea, depending on reactions in individual patients.
poveč evanjem odmerka zdravila Oprymea kot med vzdrž
Treatment discontinuation Abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome.
izzove nevroleptič maligni sindrom. ni